We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

35 hedge funds and large institutions have $52.1M invested in Eledon Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

3% more funds holding

Funds holding: 34 → 35 (+1)

6.91% less ownership

Funds ownership: 65.85% → 58.94% (-6.9%)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

30% less capital invested

Capital invested by funds: $74.5M → $52.1M (-$22.4M)

Holders
35
Holders Change
+1
Holders Change %
+2.94%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
12
Closed
4
Calls
$80K
Puts
–
Net Calls
+$80K
Net Calls Change
+$80K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$3.22M
2
BI
BVF Inc
California
+$1.75M
3
EP
Eversept Partners
New York
+$797K
4
Two Sigma Investments
Two Sigma Investments
New York
+$404K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$263K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$5.18M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.41M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.93M
5
CAM
Cormorant Asset Management
Massachusetts
-$772K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$8.43M +$1.75M +250,000 +22%
LGM
2
Logos Global Management
California
$8.28M – – –
CAM
3
Cormorant Asset Management
Massachusetts
$8.06M -$772K -110,405 -8%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$6.21M -$2.41M -345,100 -26%
WP
5
Woodline Partners
California
$4.83M -$532K -76,069 -9%
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.14M +$3.22M +460,763 +220%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$2.53M -$3.1M -443,449 -52%
IC
8
Ikarian Capital
Texas
$2.13M -$37.9K -5,422 -2%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$1.29M +$145K +20,800 +11%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$788K +$20.6K +2,944 +2%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$716K +$263K +37,600 +48%
Two Sigma Investments
12
Two Sigma Investments
New York
$713K +$404K +57,814 +101%
EP
13
Eversept Partners
New York
$705K +$797K +114,008 New
Morgan Stanley
14
Morgan Stanley
New York
$677K -$5.18M -741,548 -87%
CM
15
CM Management
Florida
$464K – – –
ISL
16
Ingalls & Snyder LLC
New York
$316K – – –
BlackRock
17
BlackRock
New York
$293K +$8.49K +1,214 +3%
State Street
18
State Street
Massachusetts
$250K +$52.4K +7,500 +23%
Renaissance Technologies
19
Renaissance Technologies
New York
$245K +$130K +18,556 +88%
BFM
20
Boothbay Fund Management
New York
$214K -$37.9K -5,422 -14%
V
21
Veritable
Delaware
$205K – – –
Northern Trust
22
Northern Trust
Illinois
$186K -$14.4K -2,063 -6%
VF
23
Virtu Financial
New York
$115K +$130K +18,610 New
Envestnet Asset Management
24
Envestnet Asset Management
Illinois
$103K +$117K +16,726 New
Mercer Global Advisors
25
Mercer Global Advisors
Colorado
$103K +$117K +16,726 New
1
2

ELDN Hedge Fund Activity: Q3 2021 in Review

35 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2021, worth a combined $52.1M — down 30% from $74.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ELDN positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 12 trimmed.

The largest buyer was Vanguard Group, adding an estimated $3.22M. The largest seller was Morgan Stanley, cutting an estimated $5.18M.

  • 35 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2021, up from 34 in Q2 2021.
  • Funds reported $52.1M of Eledon Pharmaceuticals stock for Q3 2021, down 30% quarter-over-quarter.
  • 5 funds opened new Eledon Pharmaceuticals positions in Q3 2021 and 4 closed out, a net change of +1 holder.
  • The largest Eledon Pharmaceuticals buyer in Q3 2021 was Vanguard Group, an estimated $3.22M added.
  • The largest Eledon Pharmaceuticals seller in Q3 2021 was Morgan Stanley, an estimated $5.18M sold.

Based on aggregated 13F filings for Q3 2021.